Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin A Walter

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 11, 2017
Reply: Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors: Methodologic IssuesMaria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 17, 2016
Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine TumorsMaria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 2, 2016
Upregulation of Key Molecules for Targeted Imaging and TherapyVincent F Taelman, Piotr Radojewski, Nicolas Marincek, et al.
The Cochrane Database of Systematic Reviews|November 25, 2021
Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysisMartin A Walter, Cédric Nesti, Marko Spanjol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancersLinda Villard, Anna Romer, Nicolas Marincek, et al.
Thyroid : Official Journal of the American Thyroid Association|August 14, 2016
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of ThyrotoxicosisDouglas S Ross, Henry B Burch, David S Cooper, et al.
Journal of Neuroendocrinology|November 8, 2025
Systematic review and meta-analysis of the efficacy and safety of [<sup>177</sup>Lu]Lu-edotreotide ([<sup>177</sup>Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumorsRichard P Baum, Julia G Fricke, Tristan Ruhwedel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 20, 2016
The prognostic and predictive value of sstr<sub>2</sub>-immunohistochemistry and sstr<sub>2</sub>-targeted imaging in neuroendocrine tumorsPhilippe Brunner, Ann-Catherine Jörg, Katharina Glatz, et al.
The Journal of Clinical Endocrinology and Metabolism|October 2, 2008
Impact of screening kindreds for SDHD p.Cys11X as a common mutation associated with paraganglioma syndrome type 1Mariola Peczkowska, Zoran Erlic, Michael M Hoffmann, et al.
Plos Medicine|May 13, 2025
Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single-center open-label clinical phase I trial (NEON trial)Stefan Halbherr, Stefanie Lerch, Sebastian Bellwald, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 11, 2017
Reply: Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors: Methodologic IssuesMaria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 17, 2016
Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine TumorsMaria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 2, 2016
Upregulation of Key Molecules for Targeted Imaging and TherapyVincent F Taelman, Piotr Radojewski, Nicolas Marincek, et al.
The Cochrane Database of Systematic Reviews|November 25, 2021
Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysisMartin A Walter, Cédric Nesti, Marko Spanjol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancersLinda Villard, Anna Romer, Nicolas Marincek, et al.
Thyroid : Official Journal of the American Thyroid Association|August 14, 2016
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of ThyrotoxicosisDouglas S Ross, Henry B Burch, David S Cooper, et al.
Journal of Neuroendocrinology|November 8, 2025
Systematic review and meta-analysis of the efficacy and safety of [<sup>177</sup>Lu]Lu-edotreotide ([<sup>177</sup>Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumorsRichard P Baum, Julia G Fricke, Tristan Ruhwedel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 20, 2016
The prognostic and predictive value of sstr<sub>2</sub>-immunohistochemistry and sstr<sub>2</sub>-targeted imaging in neuroendocrine tumorsPhilippe Brunner, Ann-Catherine Jörg, Katharina Glatz, et al.
The Journal of Clinical Endocrinology and Metabolism|October 2, 2008
Impact of screening kindreds for SDHD p.Cys11X as a common mutation associated with paraganglioma syndrome type 1Mariola Peczkowska, Zoran Erlic, Michael M Hoffmann, et al.
Plos Medicine|May 13, 2025
Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single-center open-label clinical phase I trial (NEON trial)Stefan Halbherr, Stefanie Lerch, Sebastian Bellwald, et al.
Pageof 8